Status: Not yet recruiting
Phase 1 Clinical Study of GenSci155 Injection in Healthy Adults
This is a Phase 1, single-center, randomized, double-blind, placebo-controlled, single and multiple intravenous ascending dose clinical study to evaluate the safety, tolerability, PK, immunogenicity, and biomarker characteristics of GenSci155 after a single or multiple intravenous injection in healthy Chinese adult trial participants.
Participants needed: 68
Trial details
Phase: Phase 1Age: 18-60Biological sex: AllType: InterventionalSponsor: Changchun GeneScience Pharmaceutical Co., Ltd.Updated: Jun 10, 2026Locations: 1
Eligibility criteria
History of hypersensitivity to IGF-1 agents or their ingredients; or a history o... [+16]